There are 392 papers on fat-free mass in aging research: 117 trials and 212 observational studies in people, 4 in animals, 54 reviews.
392 papers study it637 more mention it92 findings
57 new papers in 30 daysSee all 1,029 papers on fat-free mass
At a glance
Lower fat-free mass is associated with older age in human cohorts, while higher fat-free mass is linked with lower odds of cognitive frailty and better cognition. Human resistance-training trials report increases in fat-free mass, whereas other exercise trials report decreases or no clear effect. A caloric-restriction trial reports a decrease.
92 findings in 78 papers from 1999 to 2026, 14 of them since April 2026
“Short-term changes in HbA1c, insulin, and HOMA-IR were statistically associated with concurrent changes in FFM, MS, and RMR”
- Human trial117
- Humans212
- Animals4
- In silico1
Interventions
24Resistance training
upin humans4
4 studies
Resistance training
upin humans4
Resistance training increases fat-free mass in humans (compared with group-based dance).
Human trialcompared with group-based dance12 weeks
Resistance training increases fat-free mass in humans.
Human trialwhole body12 weeksmalesn = 39
Resistance training increases fat-free mass in humans (1.0 ± 0.3 kg).
Human trial12 weeksmalesn = 33
Resistance training increases fat-free mass in humans (experimental group, 24-week program).
Human trialexperimental group, 24-week programthree times per week24 weeksfemalesn = 69
Resistance training increases fat-free mass in humans.
Review
GLP-1 receptor agonists
downin humans3downin reviews1−40% total weight loss from ffm
4 studies
GLP-1 receptor agonists
downin humans3downin reviews1−40% total weight loss from ffm
GLP-1 receptor agonists are linked with lower fat-free mass in humans (1.8% reduction at 6 months (95% CI 1.3%-2.4%); 3.3% at 24 months).
Humansrelative change at 6 months, adjusted for age, sex, race, baseline BMI, diabetes history and treatment year6 monthsn = 1,809
GLP-1 receptor agonists decrease fat-free mass (~25% of weight loss).
Review
GLP-1 receptor agonists decrease fat-free mass in humans (up to 40% of total weight loss from FFM).
Review
GLP-1 receptor agonists decrease fat-free mass in humans (percentage of total weight lost as fat-free mass, measured by DXA) (20–40% of total weight lost as fat-free mass).
Reviewpercentage of total weight lost as fat-free mass, measured by DXA
Exercise
upin humans2no changein humans1downin humans1
4 studies
Exercise
upin humans2no changein humans1downin humans1
Exercise showed no clear effect on fat-free mass in humans.
Human trial6 monthsn = 119
Exercise decreases fat-free mass in humans (-2.8 kg (95% CI: -4.1; -1.6)).
Human trial10 weeksn = 24
Exercise increases fat-free mass in humans (-4.9 vs. -7.9 kg).
Human trialskeletal muscle6 monthsfemalesn = 80
Exercise increases fat-free mass in humans during calorie restriction (MD = +0.87 kg, 95% CI: +0.59, +1.16 kg).
Reviewduring calorie restrictionn = 1,455
Bariatric surgery
downin humans4
4 studies
Bariatric surgery
downin humans4
Bariatric surgery is linked with lower fat-free mass in humans (FFM from 61.1 ± 11.9 to 50.1 ± 7.0 kg (p < 0.001)).
Humans12 monthsn = 179
Bariatric surgery is linked with lower fat-free mass in humans (7.8% reduction at 6 months (95% CI 7.2%-8.4%); 11.7% at 24 months).
Humansrelative change at 6 months, adjusted for age, sex, race, baseline BMI, diabetes history and treatment year6 monthsn = 1,257
Bariatric surgery is linked with lower fat-free mass in humans.
Humansn = 100
Bariatric surgery decreases fat-free mass in humans (-8.23 kg [95%CI -10.74; -5.73]).
Review12-month
Semaglutide
downin humans2
2 studies
Semaglutide
downin humans2
Semaglutide is linked with lower fat-free mass in humans within semaglutide group (FFM 53.8 to 52.7 kg; p < 0.001).
Humanswithin semaglutide group12 months
Semaglutide decreases fat-free mass in humans (compared with placebo in type 2 diabetes) (MD -1.68 (95% CI -2.84 to -0.52)).
Reviewcompared with placebo in type 2 diabetes
Creatine
no changein humans1upin humans1
2 studies
Creatine
no changein humans1upin humans1
Creatine showed no clear effect on fat-free mass in humans.
Human trialn = 20
Creatine increases fat-free mass in humans during resistance training, in comparison with Pro and Pro/Col.
Human trialduring resistance training, in comparison with Pro and Pro/Col12 wkn = 49
Sukubara training system
upin humans1
1 study
Sukubara training system
upin humans1
Sukubara training system increases fat-free mass in humans (0.5 ± 0.5 vs. −0.1 ± 0.5 kg).
Human trial12 weeksn = 15
Sukubara training system increases fat-free mass in humans (0.5 ± 0.5 vs. -0.1 ± 0.5 kg).
Human trial12-weekn = 15
Bioelectrical impedance analysis
no changein humans1
1 study
Bioelectrical impedance analysis
no changein humans1
Bioelectrical impedance analysis showed no clear effect on fat-free mass in humans (type 2 diabetes mellitus) (bias +0.82 kg (95% CI −0.69 to +2.34)).
Reviewtype 2 diabetes mellitusn = 646
Synbiotics
no changein humans1
1 study
Synbiotics
no changein humans1
Synbiotics showed no clear effect on fat-free mass in humans (perimenopausal women with migraine and intestinal dysbiosis).
Human trialperimenopausal women with migraine and intestinal dysbiosis6 monthsfemales
Incretin-based therapy
downin humans1
1 study
Incretin-based therapy
downin humans1
Incretin-based therapy decreases fat-free mass in incretin-based trials (-6.8% to -10.9%; 33%-38% of total weight loss).
Reviewin incretin-based trials
Gochujang
upin humans1
1 study
Gochujang
upin humans1
Gochujang increases fat-free mass in humans (compared with baseline and other groups as reported).
Human trialcompared with baseline and other groups as reportedlow-Gochujang8 weeksfemales
Low-calorie diet
downin humans1
1 study
Low-calorie diet
downin humans1
Low-calorie diet decreases fat-free mass in humans (combined with tirzepatide; compared with low-energy ketogenic therapy) (significantly greater FFM reduction than TZP+LEKT (p = 0.0388)).
Human trialcombined with tirzepatide; compared with low-energy ketogenic therapy12 weeks
Caloric restriction
downin humans1
1 study
Caloric restriction
downin humans1
Caloric restriction decreases fat-free mass in humans (−4.29% ± 1.31 vs. −0.50% ± 0.82).
Human trial12 weeksn = 60
Time-restricted feeding
downin humans1
1 study
Time-restricted feeding
downin humans1
Time-restricted feeding decreases fat-free mass in young adults with overweight or obesity.
Human trialin young adults with overweight or obesityeight weeksn = 16
Combined exercise and dietary intervention
no changein humans1
1 study
Combined exercise and dietary intervention
no changein humans1
Combined exercise and dietary intervention showed no clear effect on fat-free mass in patients with ovarian cancer during and after chemotherapy (β = -0.5 kg, 95% CI -3.2 to 2.1).
Human trialin patients with ovarian cancer during and after chemotherapyfemalesn = 81
All 24Fewer
Effects
2Cognitive function
upin humans1OR 1.081
1 study
Cognitive function
upin humans1OR 1.081
Fat-free mass is linked with better cognitive function in humans (OR 1.081, 95% CI 1.045-1.119).
Humans
Isotope dilution space ratio
no changein humans1
1 study
Isotope dilution space ratio
no changein humans1
Fat-free mass was not clearly linked with isotope dilution space ratio in humans.
Humans
Upstream
2Age
downin humans2
2 studies
Age
downin humans2
Age is linked with lower fat-free mass in humans.
Humansmales
Age is linked with lower fat-free mass in humans.
Humansn = 3,451
Chronic obstructive pulmonary disease
downin humans1
1 study
Chronic obstructive pulmonary disease
downin humans1
Chronic obstructive pulmonary disease is linked with lower fat-free mass in humans (patients with COPD) (-1173 [-1527/-820] g).
Humanspatients with COPD2 yearsn = 205
Associations
42Bioelectrical impedance analysis
upin humans2
2 studies
Bioelectrical impedance analysis
upin humans2
Bioelectrical impedance analysis is associated with fat-free mass in humans (mean difference 0.52 kg).
Humansfemalesn = 79
Bioelectrical impedance analysis is associated with fat-free mass in humans (compared with anthropometric tools in 14 centenarians in Italy).
Reviewcompared with anthropometric tools in 14 centenarians in Italyn = 14
Resting energy expenditure
upin humans2
2 studies
Resting energy expenditure
upin humans2
Fat-free mass is associated with resting energy expenditure in adapted patients with obesity.
Humansin adapted patients with obesityn = 23
Fat-free mass is associated with resting energy expenditure in humans.
Humansn = 72
Sarcopenia
downin humans1upin humans1
2 studies
Sarcopenia
downin humans1upin humans1
Sarcopenia is associated with fat-free mass in humans (compared to control group).
Humanscompared to control group
Sarcopenia is associated with fat-free mass in humans (nursing home residents).
Humansnursing home residentsn = 66
Age
downin humans2
2 studies
Age
downin humans2
age is associated with fat-free mass in humans (adjusted for covariates; changes from age 60 to 90 years) (-2.8 kg (women), -3.5 kg (men)).
Humansadjusted for covariates; changes from age 60 to 90 yearsn = 401
Age is associated with fat-free mass in humans (r = -0.25).
Humansmalesn = 102
Hand grip strength
upin humans1
1 study
Hand grip strength
upin humans1
Fat-free mass predicts hand grip strength in humans (multivariate analysis).
Humansmultivariate analysisn = 109
Fat-free mass is associated with hand grip strength in humans.
Humansn = 109
Total mortality
downin humans1HR 0.96
1 study
Total mortality
downin humans1HR 0.96
Fat-free mass is associated with total mortality in humans (full cohort) (HR 0.96, 95% CI 0.93–1.00).
Humansfull cohortfemalesn = 3,439
10-year ASCVD risk
downin humans1
1 study
10-year ASCVD risk
downin humans1
Fat-free mass is associated with 10-year ASCVD risk in humans (Sex-adjusted linear regression).
HumansSex-adjusted linear regressionn = 761
HbA1c
upin humans1
1 study
HbA1c
upin humans1
Fat-free mass is associated with HbA1c in humans (total FFM and FFM/height2 tertiles).
Humanstotal FFM and FFM/height2 tertilesn = 59,269
Fat-free mass links to metabolic health varied with deep belly fat
The Journal of clinical endocrinology and metabolism
Metabolic syndrome
upin humans1
1 study
Metabolic syndrome
upin humans1
Fat-free mass is associated with metabolic syndrome in humans (total FFM and FFM/height2 tertiles).
Humanstotal FFM and FFM/height2 tertilesn = 59,269
Fat-free mass links to metabolic health varied with deep belly fat
The Journal of clinical endocrinology and metabolism
Migraine disability
downin humans1
1 study
Migraine disability
downin humans1
Fat-free mass is associated with migraine disability in humans (perimenopausal women with migraine and intestinal dysbiosis) (rho = −0.667, p = 0.009).
Human trialperimenopausal women with migraine and intestinal dysbiosisfemalesn = 14
HbA1c, insulin and HOMA-IR
mixedin humans1
1 study
HbA1c, insulin and HOMA-IR
mixedin humans1
Fat-free mass is associated with HbA1c, insulin and HOMA-IR in humans.
Human trialduring tirzepatide therapy; concurrent changes in muscle strength and resting metabolic rate12 weeks
All 42Fewer
Funding
1 grant since 2021National Institute of Diabetes and Digestive and Kidney Diseases$648K
How this record changed
Summary rewritten as its findings changed.
As it read before
Human studies associate fat-free mass with metabolic syndrome, HbA1c, eGFR and a prudent dietary pattern. A human-trial preprint links higher fat-free mass to less migraine disability in perimenopausal women with migraine and intestinal dysbiosis, but reports no change in fat-free mass after six months of prebiotics plus probiotics in this group.
Summary written from the findings.